ADHD spend to increase 13-fold

Attention-deficiency hyperactivity disorder (ADHD) drug costs for the NHS are set to soar with increased diagnosis of the condition in children and adolescents in the UK, claim German researchers.

The estimated £7 million spend on ADHD by the NHS in 2002 is expected to rise to between £49 and £101 million a year by 2012. The overall drug expenditure by individual doctors for ADHD may increase nine-fold.

Professor Michael Schlander, from the University of Heidelberg calculated the range of possible costs by considering likelihood of diagnosis and treatment, the level of treatment and drug costs.

The calculation is based on the assumption that ADHD has, until recently, been undiagnosed in the UK. In turn, the number of scrips for ADHD drugs has increased.

A BBC Panorama programme led to reports that the drugs offer no long-term benefit.

These claims were based on a three-year follow-up study that showed little difference between children with ADHD managed with drugs and those given behavioural or routine care.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from the shielded patient list in a future wave of...

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide care to shielded patients in 'infection-controlled clinical settings'...

How digital assistants can help patients manage their health and wellbeing

How digital assistants can help patients manage their health and wellbeing

A project in Staffordshire has shown how practices can make use of digital technology...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

The government must do ‘the right thing’ and secure adequate death-in-service benefits...

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP practices are being contacted by patients asking for antibody tests as the government...